This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn's disease.View ENZN
Enzon Pharmaceuticals Inc - ENZN - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Enzon Pharmaceuticals Inc as a
Hold with a ratings score of C-.
Report Snippet: We rate ENZON PHARMACEUTICALS INC (ENZN) a HOLD. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and attractive valuation levels. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself.